Repligen (NASDAQ:RGEN) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen cut shares of Repligen (NASDAQ:RGEN) from a buy rating to a hold rating in a research report report published on Tuesday morning.

A number of other analysts also recently issued reports on RGEN. Wells Fargo & Company dropped their price objective on shares of Repligen from $180.00 to $175.00 and set an “overweight” rating for the company in a report on Wednesday, July 30th. HSBC began coverage on shares of Repligen in a report on Wednesday, October 1st. They set a “buy” rating and a $150.00 price objective for the company. Hsbc Global Res raised shares of Repligen to a “strong-buy” rating in a report on Wednesday, October 1st. Weiss Ratings reiterated a “sell (d)” rating on shares of Repligen in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group set a $160.00 target price on shares of Repligen and gave the stock a “hold” rating in a research report on Tuesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $173.85.

Repligen Stock Performance

NASDAQ RGEN opened at $146.93 on Tuesday. Repligen has a 52-week low of $102.96 and a 52-week high of $182.52. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59. The company has a market capitalization of $8.27 billion, a P/E ratio of 7,350.18, a P/E/G ratio of 3.32 and a beta of 1.08. The company has a fifty day moving average of $136.52 and a 200-day moving average of $129.15.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.04. Repligen had a net margin of 0.25% and a return on equity of 4.70%. The company had revenue of $188.80 million during the quarter, compared to the consensus estimate of $181.23 million. During the same period in the previous year, the firm posted $0.43 EPS. The firm’s revenue was up 21.9% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. As a group, equities research analysts predict that Repligen will post 1.72 EPS for the current fiscal year.

Insider Activity

In other news, Director Martin D. Madaus acquired 1,800 shares of the firm’s stock in a transaction on Friday, August 8th. The shares were purchased at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the transaction, the director owned 1,800 shares of the company’s stock, valued at $201,834. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Repligen

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Harvest Fund Management Co. Ltd purchased a new stake in Repligen in the first quarter worth about $132,000. XTX Topco Ltd lifted its position in Repligen by 34.2% during the first quarter. XTX Topco Ltd now owns 12,935 shares of the biotechnology company’s stock valued at $1,646,000 after purchasing an additional 3,295 shares during the period. Congress Asset Management Co. lifted its position in Repligen by 18.0% during the second quarter. Congress Asset Management Co. now owns 152,450 shares of the biotechnology company’s stock valued at $18,962,000 after purchasing an additional 23,231 shares during the period. Dynamic Technology Lab Private Ltd raised its position in Repligen by 233.6% in the first quarter. Dynamic Technology Lab Private Ltd now owns 9,208 shares of the biotechnology company’s stock worth $1,172,000 after acquiring an additional 6,448 shares during the period. Finally, TD Asset Management Inc raised its position in Repligen by 10.9% in the first quarter. TD Asset Management Inc now owns 51,172 shares of the biotechnology company’s stock worth $6,511,000 after acquiring an additional 5,014 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.